10-Q: Cell Source, Inc. Q1 2025 Update: Net Loss Widens Amidst Funding Efforts

Cell Source, Inc. reported a net loss of $1.48 million for Q1 2025, with significant increases in R&D expenses and interest costs, while actively pursuing capital raises to address going concern issues.

Summary

• Cell Source, Inc. reported a net loss of $1,481,851 for the three months ended March 31, 2025, compared to a net loss of $1,275,406 for the same period in 2024.
• Total operating expenses decreased by 12% to $998,587 in Q1 2025 from $1,138,129 in Q1 2024, primarily due to a reduction in general and administrative expenses.
• Research and development expenses increased by 45% to $515,183 in Q1 2025 from $356,213 in Q1 2024, driven by new amendments with MD Anderson.
• Interest expense significantly increased by 92% to $427,237 in Q1 2025 from $222,814 in Q1 2024, and amortization of debt discount rose by 1,354% to $86,637.
• The company had a working capital deficiency of $20,136,000 as of March 31, 2025, and an accumulated deficit of $47,662,000.
• As of March 31, 2025, notes payable and convertible notes payable totaling approximately $6,328,000 were past due, increasing to $11,116,000 through the filing date.
• The company is actively negotiating to raise additional capital through debt and equity financings to address its going concern status.
• Subsequent to March 31, 2025, the company received approximately $2.84 million from note payable issuances, $310,000 from Series B Convertible Preferred Stock, and $100,000 from Common Stock issuances.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing negatively due to the widening net loss, critical liquidity situation, substantial past-due debt, and the explicit statement of substantial doubt about the company's ability to continue as a going concern, despite ongoing financing efforts.

Positives

• General and administrative expenses decreased by 38% to $483,404 in Q1 2025 from $781,916 in Q1 2024, attributed to reduced consulting and stock-based compensation expenses.
• The Phase 1/2 clinical trial at MD Anderson Cancer Center using Anti-viral Veto Cells has shown no toxicity associated with Veto Cells and consistent successful stem cell engraftment without severe GvHD.
• Subsequent to the quarter, the company received significant proceeds from various financing activities, including notes payable, Series B Convertible Preferred Stock, and Common Stock issuances, totaling approximately $3.25 million.

Negatives

• The company reported a net loss of $1,481,851 for the three months ended March 31, 2025, an increase from the prior year's loss of $1,275,406.
• Cash decreased significantly from $74,631 at the end of 2024 to $1,240 as of March 31, 2025.
• The company has a substantial working capital deficiency of $20,136,000 as of March 31, 2025.
• A significant amount of debt, $6,328,000 as of March 31, 2025, and $11,116,000 through the filing date, is past due.
• The company's ability to continue as a going concern is in substantial doubt due to its net losses, working capital deficiency, and past-due debt.

Risks

• The company's ability to continue as a going concern is in substantial doubt due to its recurring net losses, working capital deficiency, and significant past-due debt.
• Failure to obtain additional financing on a timely basis could force the company to curtail development, marketing, and promotional activities, potentially leading to discontinuation of operations and liquidation.
• The ongoing war in Ukraine, the Israel-Hamas conflict, and the United States/Israel-Iran war, along with other geopolitical and macroeconomic events, could have unpredictable impacts on the company's business.
• The company is heavily reliant on the success of its Veto Cell technology and its ability to secure further funding for its development and commercialization.

Future Outlook

The company is actively seeking additional capital through debt and equity financings to fund its development activities and achieve profitability. There is no assurance that these efforts will be successful, and failure to secure financing could lead to curtailment of operations or liquidation. The company plans to submit a clinical protocol for allogeneic VETO CAR-T HSCT combined therapy for blood cancer treatment in 2026.

Management Comments

• The company is currently funding its operations on a month-to-month basis and is in active negotiations to raise additional capital.
• Managements plans include continued efforts to raise additional capital through debt and equity financings.
• There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations.
• If the Company is unable to obtain such additional financing on a timely basis or, notwithstanding any request the Company may make, if the Company's debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company's business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.

Industry Context

StockSavvy.ai notes that Cell Source, Inc. operates in the highly competitive and capital-intensive biotechnology sector, focusing on cell therapy for cancer and organ transplantation. The company's reliance on external financing and the significant clinical development risks are common within this industry. The reported increase in R&D spending aligns with industry trends for companies advancing novel therapeutic technologies.

Comparison to Industry Standards

• The net loss of $1.48 million for the quarter is substantial for a company at this stage, but not uncommon for early-stage biotechnology firms investing heavily in R&D. However, the significant increase in interest expense and the large amount of past-due debt are concerning compared to industry peers who typically maintain more robust cash reserves or have secured longer-term financing.
• The company's cash burn rate of approximately $600,000 per quarter for operations, coupled with a minimal cash balance of $1,240, indicates a critical need for immediate funding. Many biotech companies in clinical development aim for cash runway of 12-18 months, which Cell Source currently lacks.
• The progress in the Phase 1/2 clinical trial at MD Anderson, showing no toxicity and successful engraftment, is a positive indicator. However, the path to regulatory approval and commercialization for cell therapies is long and expensive, with many competitors also developing similar or alternative treatments.

Legal Proceedings

• No pending legal proceedings or litigations are disclosed, and no governmental authority is contemplating any proceeding that would likely have a material adverse effect.

Related Party Transactions

• Accrued expenses - related party: $217,000 as of March 31, 2025.
• Accrued interest - related parties: $2,193,741 as of March 31, 2025.
• Notes payable - related parties: $795,345 as of March 31, 2025.
• Convertible notes payable - related parties: $7,561,708 as of March 31, 2025.
• Derivative liabilities - related party: $151,228 as of March 31, 2025.
• In January 2025, the company issued an Original Issue Discount Promissory Note in the principal amount of $385,860 to George Verstraete, a member of the Board of Directors, for a purchase price of $327,000. A warrant to purchase 490,500 shares of common stock was issued in connection with this transaction.
• The company accrued $131,792 for the fair value of obligations to issue warrants to former directors in connection with loans totaling $459,000.
• Notes payable to related parties are detailed in Note 5, including a $327,000 issuance in Q1 2025 with a maturity date of April 27, 2025, bearing 12% interest and an original issue discount.

Stakeholder Impact

• Shareholders: The company's going concern issues and potential for liquidation pose a significant risk to shareholder value. Dilution is likely with ongoing capital raises.
• Creditors: A substantial amount of debt is past due, increasing the risk of default and potential legal action. The company is actively negotiating with debt holders.
• Employees/Consultants: The company currently has minimal full-time employees and relies on independent contractors. Future operational curtailment could impact these service providers.
• Investors: The company's ability to secure future funding is critical. Recent financing activities indicate continued investor interest, but the terms and amounts may not be sufficient to ensure long-term viability.

Next Steps

• Continue active negotiations to raise additional capital through debt and equity financings.
• Submit clinical protocol for allogeneic VETO CAR-T HSCT combined therapy for blood cancer treatment in 2026.
• Continue Phase 1/2 clinical trial at MD Anderson Cancer Center with additional cohorts of patients.

Key Dates

Recommendation

The company's severe liquidity crisis, substantial past-due debt, and explicit going concern warnings, despite ongoing financing efforts, present an extremely high risk. The net loss has widened, and cash reserves are critically low. While the Veto Cell technology shows promise, the immediate financial distress makes the stock a speculative investment with a high probability of further decline or complete loss.

Keywords

Cell Source, 10-Q, Biotechnology, Cancer Treatment, Immune Tolerance, Veto Cell Technology, Stem Cell Transplantation, CAR-T Therapy, Clinical Trial, Financing, Going Concern, SEC Filing